Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2342564
下载链接
链接失效反馈官方服务：
资源简介：
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China. About 268 eligible metastatic colorectal cancer patients after second-line therapy will be assigned to receive either regorafenib or fruquintinib, based on decision of the gastrointestinal physician according the patients’ condition.
创建时间：
2020-05-15
